Armistice Capital »

Kymera Therapeutics shares owned by Armistice Capital

Quarter-by-quarter ownership of Kymera Therapeutics (KYMR) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Kymera Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kymera Therapeutics held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kymera Therapeutics by Armistice Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $7.0M 84k 83.29

More positions owned by Armistice Capital

State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Agios Pharmaceuticals (AGIO)
Cytokinetics Com New (CYTK)
Ptc Therapeutics I (PTCT)
Travere Therapeutics (TVTX)
Madrigal Pharmaceuticals (MDGL)
Immunovant (IMVT)
Supernus Pharmaceuticals (SUPN)
Neurocrine Biosciences (NBIX)
Freshpet (FRPT)
Incyte Corporation (INCY)
Dyne Therapeutics (DYN)
Amazon (AMZN)
Ironwood Pharmaceuticals Com Cl A (IRWD)

View all positions for Armistice Capital

Top funds holding Kymera Therapeutics

FMR
Baker Bros. Advisors
venBio Select Advisor
Vanguard Group
BVF
BlackRock
Atlas Venture Life Science Advisors
Wellington Management Company
Siren
Vanguard Capital Management
Vanguard Portfolio Management
State Street Corporation
Capital Research Global Investors
Geode Capital Management
Driehaus Capital Management

View all funds holding Kymera Therapeutics